Learn About Gaucher Disease Type 3

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Gaucher Disease Type 3 Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the Latest Advances for Gaucher Disease Type 3?
Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
Tired of the same old research?
Check Latest Advances
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
What are the latest Gaucher Disease Type 3 Clinical Trials?
OMICS GAUCHER STUDY: MULTIOMIC APPROACH TO DESCRIBE THE GAUCHER DISEASE TREATMENT DYNAMICS IN COMPARISON TO UNTREATED HEALTHY VOLUNTEERS

Summary: The study aims to investigate the transcriptomic and metabolomic changes in blood, plasma and isolated monocytes from Gaucher patients and healthy controls.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Post Marketing Surveillance (PMS) Study for VPRIV (Velaglucerase Alfa) in India

Summary: The purpose of this post-marketing survey study is to determine the safety and evaluate effectiveness in participants receiving VPRIV when used in the post-marketing setting and to collect and record genetic mutation data from participants with Gaucher disease.